APVO - Aptevo Therapeutics - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

-11.67M

Cash

21.01M

Avg Qtr Burn

-3.268M

Short % of Float

1.13%

Insider Ownership

1.10%

Institutional Own.

12.23%

Qtr Updated

06/30/23

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
APVO436 (anti-CD123 x anti-CD3) +/- Venetoclax + Azacitidine Details Myelodysplastic syndrome, Acute myeloid leukemia, Cancer	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
ALG.APV-527 (4-1BB x 5T4) Details Cancer, Solid tumor/s, Colorectal cancer , Pancreatic cancer, Non-small cell lung carcinoma, Breast cancer	Phase 1 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.